Cove Street Capital LLC maintained its position in shares of Trinity Biotech PLC (NASDAQ:TRIB) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 200,000 shares of the company’s stock at the close of the 2nd quarter. Cove Street Capital LLC owned 0.92% of Trinity Biotech PLC worth $1,200,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in shares of Trinity Biotech PLC by 21.1% in the 1st quarter. Renaissance Technologies LLC now owns 164,650 shares of the company’s stock worth $981,000 after purchasing an additional 28,700 shares during the last quarter. Teton Advisors Inc. increased its position in shares of Trinity Biotech PLC by 0.3% in the 2nd quarter. Teton Advisors Inc. now owns 231,730 shares of the company’s stock worth $1,390,000 after purchasing an additional 800 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Trinity Biotech PLC by 19.4% in the 2nd quarter. Russell Investments Group Ltd. now owns 457,577 shares of the company’s stock worth $2,745,000 after purchasing an additional 74,374 shares during the last quarter. Hunter Associates Investment Management LLC increased its position in shares of Trinity Biotech PLC by 29.0% in the 2nd quarter. Hunter Associates Investment Management LLC now owns 599,600 shares of the company’s stock worth $3,598,000 after purchasing an additional 134,850 shares during the last quarter. Finally, First Wilshire Securities Management Inc. increased its position in shares of Trinity Biotech PLC by 21.7% in the 1st quarter. First Wilshire Securities Management Inc. now owns 1,075,221 shares of the company’s stock worth $6,408,000 after purchasing an additional 191,650 shares during the last quarter. 62.97% of the stock is owned by institutional investors.

Several equities research analysts have recently weighed in on the stock. ValuEngine downgraded shares of Trinity Biotech PLC from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded shares of Trinity Biotech PLC from a “buy” rating to a “hold” rating in a research report on Wednesday, September 20th.

Shares of Trinity Biotech PLC (TRIB) traded down 2.52% during midday trading on Monday, hitting $5.42. 3,020 shares of the company were exchanged. Trinity Biotech PLC has a one year low of $5.11 and a one year high of $13.34. The stock’s 50-day moving average is $5.44 and its 200-day moving average is $5.63. The stock’s market cap is $118.41 million.

Trinity Biotech PLC (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, July 20th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03). Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. The company had revenue of $25.45 million during the quarter, compared to the consensus estimate of $24.83 million. Equities research analysts anticipate that Trinity Biotech PLC will post $0.27 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Trinity Biotech PLC (TRIB) Position Maintained by Cove Street Capital LLC” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/09/25/trinity-biotech-plc-trib-position-maintained-by-cove-street-capital-llc.html.

Trinity Biotech PLC Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Want to see what other hedge funds are holding TRIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Trinity Biotech PLC (NASDAQ:TRIB).

Institutional Ownership by Quarter for Trinity Biotech PLC (NASDAQ:TRIB)

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.